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Prostatic carcinoma is one of the major cancers in men. It is known
that the progression of the disease is highly associated with meta-
stasis to the bone and the lymph nodes (Slack et al, 1986). The
major therapy for extensive disease is androgen deprivation
therapy, whereas there are several ways to treat localized (non-
metastatic) prostatic cancer, including anti-androgen therapy,
radical prostatectomy, radiotherapy and cryotherapy. The prog-
nosis is dependent on the presence of lymph node metastasis
(Epstein et al, 1996). However, the molecular mechanisms under-
lying lymph node metastasis are poorly examined.
Vascular endothelial growth factor (VEGF)/vascular perme-
ability factor (VPF) belongs to the platelet-derived growth factor
(PDGF)/VEGF family, which is known as a potent inducer of
angiogenesis (Dvorak et al, 1995; Ferrara and Davis-Smyth,
1997). VEGF receptor-1 (VEGFR-1; Flt-1) and VEGFR-2 (Flk-
1/KDR) are receptor tyrosine kinases for VEGF/VPF (Ferrara and
Davis-Smyth, 1997). These receptors are found to be largely
expressed on the vascular endothelial cells. VEGFR-2 has an
ability to transduce signals for biological responses leading to
angiogenesis, including proliferation and migration of endothelial
cells in vitro, whereas the significance of Flt-1 was unclear
(Waltenberger et al, 1994). Recently, Flt-1 was reported to trans-
duce signals for migration and activation of monocytes (Barleon et
al, 1996; Clauss et al, 1996). Gene targeting of VEGFR-1 and
VEGFR-2 results in the fetal death associated with the lack of
normal vasculature in utero (Fong et al, 1995; Shalabi et al, 1995),
indicating that VEGF receptors are important for vascular devel-
opment. Recently, new members of the VEGF/VPF family,
denoted VEGF-C and -D, were cloned (Joukov et al, 1996; Achen
et al, 1998). Receptors for VEGF-C and -D are VEGFR-3 (Flt-4)
(Pajusola et al, 1992) and VEGFR-2. VEGFR-2 has an affinity for
VEGF/VPF, whereas VEGFR-3 can bind specifically to VEGF-C
and -D. The distribution of VEGFR-3 is highly restricted to the
lymphatic endothelial cells (Kaipainen et al, 1995), suggesting that
VEGFR-3 is one of the specific markers for lymphatic endothelial
cells. VEGF-C-transgenic mice revealed that an increase in the
diameter of lymphatic vessels was the major effect of VEGF-C
overexpression instead of an increase in number of vessels (Jeltsch
et al, 1997). In contrast, VEGF-C-coated thermanox disks
markedly induced lymphangiogenesis (increase in number of
lymphatic vessels) in the differentiated avian chorioallantoic
membrane (Oh et al, 1997). These results suggest differences in
the effects of VEGF-C on embryonic and mature lymphatic
vessels.
In this study, we examined the expression of VEGF-C in human
prostatic carcinoma tissue and found that there was a significant
correlation between the expression of VEGF-C and lymph node
dissemination. Additionally, the number of VEGFR-3-positive
vessels was increased in the surrounding stromal tissue of VEGF-
C positive prostatic carcinoma cells. These results indicate that the
determination of VEGF-C expression in prostatic carcinoma tissue
would be useful to predict lymph node metastasis and suggest a
role for VEGF-C in lymphatic metastasis.
MATERIALS AND METHODS
Tissue collection and preparation, and patients’
characteristics
Prostate cancer tissues from 26 patients were used in this study.
All tissue specimens were obtained by 16- or 18-gauge needle
transperineal biopsies under informed consent prior to treatment.
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Correspondence to: S KandaTissue specimens for in situ hybridization (ISH) were fixed in 10%
neutral buffered formalin and embedded in paraffin, and some
specimens for immunohistochemistry (IHC) were kept as fresh
frozen sections. Histological grade was determined in each sample
by using the Gleason grading system (Gleason et al, 1977) and the
tissue area containing the primary grade site (predominant) was
selected for further investigation. Serum prostatic specific antigen
(PSA) was measured prior to the biopsy by using Tandem R assay.
Patients were examined for detection of metastasis with chest X-
ray, abdominal ultrasonography, computerized tomography scan-
ning, magnetic resonance imaging and bone scintigraphy, and
clinical stage was assessed by the 1992 TNM system (Hermanek
and Sobin, 1992). Patients were divided into three groups: group 1
consisted of seven cases with clinically localized, well-differenti-
ated (Gleason score 2–4) prostatic adenocarcinoma; group 2
consisted of ten cases with bone metastases, which are thought to
be the metastatic sites via blood vessels; and group 3 consisted of
nine cases with both bone and lymph node metastases. The mean
ages of patients in each group were 74.0, 75.0 and 69.6 years old,
respectively, and the differences were not statistically significant.
There was no statistical difference in Gleason score and T stage
between group 2 and group 3.
Preparation of oligo-DNA probes
A 40-base sequence complementary to VEGF-C mRNA was
selected. The antisense and sense sequences were synthesized
together with two and three TTA repeats at the 5¢- and 3¢-ends
of sequences for the T-T dimer formation. The sequences




CAATTATTATT-3¢, respectively. A computer-assisted search
(GenBank Rel. 95.0, 1996) of the above antisense sequence, as
well as the sense sequence, showed no significant homology with
any known sequences. The T-T dimer, which is used to provide a
hapten for antibody recognition of the ISH probes (Koji et al,
1996), was introduced into oligo-DNAs by UV irradiation (254
nm) with a dose of 12 000 J m–2. The generation of T-T dimer was
verified immunochemically by using mouse monoclonal anti-T-T
IgG (Kyowa Medex, Tokyo, Japan).
Dot-blot hybridization
Various amounts of the sense oligo-DNA between 1 pg and 10 ng
were spotted onto nitrocellulose membranes that had been soaked
in 20 ´ suline–sodium citrate (SSC) [1 ´ SSC; 0.015 M sodium
citrate, pH 7.0 supplemented with 0.15 M sodium chloride
(NaCl)]. After air-drying, the filters were baked at 80°C for 2 h,
followed by the incubation with prehybridization medium
containing 10 mM Tris-HCl, pH 7.4, 0.6 M NaCl, 1 mM EDTA,
1 ´ Denhardt’s solution, 500 mg ml–1 yeast tRNA, 250 mg ml–1
salmon testicular DNA (Sigma, St Louis, MO, USA) and 40%
(v/v) deionized formamide at 37°C for 2 h. The membranes were
then incubated with 1 mg ml–1 T-T dimerized oligo-DNA probe in
hybridization medium containing 10 mM Tris-HCl (pH 7.4), 0.6 M
NaCl, 1 mM EDTA, 1 ´ Denhardt’s solution, 250 mg ml–1 yeast
tRNA, 125 mg ml–1 salmon testicular DNA, 10% dextran sulphate
and 40% deionized formamide at 37°C overnight. After washing
with 2 ´ SSC, the membranes were stained immunochemically
with anti-T-T IgG as described previously (Koji et al, 1996) and
the signals were visualized by the incubation with 0.1 M phosphate
buffer, pH 7.5, containing 0.15 mg ml–1 3,3¢-diaminobenzidine-4
hydrochloric acid (HCl) (DAB), 0.01% hydrogen peroxide (H2O2),
0.025% CoCl2 and 0.02% NiSO4(NH4)2SO4 (Adams, 1981).
ISH for cultured cells
Human prostatic adenocarcinoma cell lines, PC-3, DU145 and
LNCap cells were grown in Ham’s F-12 medium supplemented
with 10% heated-inactivated fetal bovine serum (Life Tech.
Oriental, Tokyo, Japan). For ISH, cells were seeded into wells of
8-well Lab-Tek chamber glass slides (Nalge Nunc International,
Naperville, IL, USA) and cultured overnight. ISH of these cells
was performed according to the method described previously
(Koji et al, 1996; Tsurusaki et al, 1998). Briefly, cells grown on
glass slides were sequentially incubated with 0.2 N HCl for
20 min, 0.2% Triton X-100 in phosphate-buffered saline (PBS) for
10 min, and 2 mg ml–1 proteinase K at 37°C for 20 min. After fixa-
tion with 4% paraformaldehyde in PBS for 5 min, the cells were
immersed in PBS containing 2 mg ml–1 glycine for 30 min and
kept in 4 ´ SSC containing 40% deionized formamide until use for
hybridization. Hybridization was carried out at 37°C overnight
with 2 mg ml–1 T-T dimerized antisense oligo-DNA for VEGF-C
dissolved in hybridization medium. The cells were washed with
50% formamide in 2 ´ SSC for 5 h followed by washing with PBS,
and were then incubated with anti-T-T dimer monoclonal antibody
followed by the incubation with peroxidase-conjugated anti-
mouse IgG. Peroxidase bound to tissue sections was visualized as
described previously (Koji et al, 1996; Tsurusaki et al, 1998).
Hybridization signals were considered positive when accumulated
black deposits were seen in individual cells. When the signal was
similar to that of the negative control, the sample was regarded as
‘negative’. ‘Weak positive’ staining was assigned when the signals
were present, but only localized to the perinuclear area. ‘Strong
positive’ staining represented dense and clear signals throughout
the cytoplasm.
ISH for prostatic carcinoma specimens
Deparaffinized and rehydrated biopsy specimens were sequen-
tially treated with 0.3% H2O2 in methanol for 15 min, 0.2 N HCl
for 20 min and 100 mg ml–1 proteinase K at 37°C for 15 min. ISH
for biopsy specimens was performed according to the method
discribed in ISH for cultured cells.
Control experiments for ISH
To evaluate the specificity of VEGF-C mRNA signals, a panel of
control experiments were conducted on sections adjacent to the
malignant area (Koji et al, 1996; Tsurusaki et al, 1998). A number of
consecutive tissue sections were hybridized with T-T dimerized
oligo-DNA complementary to 28S rRNA as a positive control
(Yoshii et al, 1995) and also T-T dimerized VEGF-C sense oligo-
DNA as a negative control in every run. Another group of tissue
sections was hybridized with the VEGF-C antisense probe in the
presence of an excess amount (50-fold) of either homologous or non-
homologous unlabelled oligo-DNA probe, to confirm the sequence
specificity of the signals. To eliminate possible involvement of
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digested with 100 mg ml–1 of ribonuclease-A (RNase-A) at 37°C
for 60 min before the post-fixation step. In some sections, exces-
sively stringent washing conditions (50% formamide in 2 ´ SSC at
37°C for 5 h and 50% formamide in 0.1 ´ SSC at 45°C for 30 min)
were applied after hybridization with the VEGF-C antisense
probes.
IHC for VEGFR-3
The monoclonal antibody raised against the extracellular domain
of human VEGFR-3 (mouse IgG1) (Jussila et al, 1998) was used.
The antibody could recognize VEGFR-3 expressed in tissues
prepared as frozen sections. Fresh frozen prostatic tissue sections
from six patients (two sections each from VEGF-C-negative,
VEGF-C weakly positive and VEGF-C strongly positive cancer
tissues) were fixed with acetone at 4°C and treated with 5%
normal goat serum in 1% bovine serum albumin in PBS. Then the
sections were incubated with 2 mg ml–1 monoclonal antibody at
room temperature overnight and then with horseradish peroxidase
(HRP) conjugated goat anti-mouse IgG for 60 min. Peroxidase
was visualized with DAB and H2O2, and the sections were
counterstained with methyl green and mounted. The consecutive
sections were incubated with 2 mg ml–1 normal mouse IgG in place
of the specific monoclonal antibody and used as a negative control.
Statistical analysis
The  c2 test was used to analyse the relationship of VEGF-C
mRNA expression between groups 1 + 2 and 3.
RESULTS
Dot-blot hybridization with T-T dimerized synthetic
oligo-DNA
To examine the sensitivity of synthesized antisense oligo-DNA,
VEGF-C sense oligo-DNA on a nitrocellulose membrane was
hybridized with T-T dimerized VEGF-C antisense oligo-DNA or
T-T dimerized VEGF-C sense oligo-DNA. One picogram of the
sense DNA was detected with the antisense probe, while the sense
oligo-DNA detected no signal (data not shown). These results
indicate that the antisense probe was specific and had adequate
sensitivity to be used in ISH studies.
VEGF-C mRNA expression in cultured human prostatic
carcinoma cells assessed by ISH
To certify the quality of T-T dimerized VEGF-C antisense oligo-
DNA in ISH study, expression of mRNA for VEGF-C in PC-3,
LNCaP and DU145 cells was examined. VEGF-C mRNA was
expressed in the cytoplasmic area of more than 90% of these cells.
In LNCaP cells, high expression of VEGF-C was observed, and
DU145 cells were found to express low amount of VEGF-C
mRNA. To confirm the sequence specificity of the VEGF-C
mRNA signal in these cell lines, we conducted various control
experiments. A representative set of control experiments on PC-3
was shown in Figure 1A, B and D–G. When cells were hybridized
with the T-T dimerized oligo-DNA complementary to 28S rRNA,
signals were detected in the cytoplasmic area as well as in nucleoli
(Figure 1A), whereas no staining was found with T-T dimerized
VEGF-C sense probe (Figure 1B). When cells were hybridized
with VEGF-C antisense probe in the presence of excess amount of
the homologous unlabelled oligo-DNA, cytoplasmic signal was
much weaker (Figure 1D). On the other hand, the VEGF-C mRNA
staining was not altered by the presence of excess amount of non-
homologous unlabelled oligo-DNA (Figure 1E). When cells were
washed at excessively high stringency or were digested with
RNase-A, a remarkable decrease in the staining was observed
(Figure 1F, G).
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Table 1 Summary of VEGF-C mRNA expression in primary prostatic
carcinoma specimens determined by in situ hybridization
Group 1 Group 2 Group 3
Gleason sum 4 ± 0 8.2 ± 1.1 8.9 ± 0.9
PSA (ng ml–1) 18.3 ± 10.9 213.2 ± 393.9 622.3 ± 799.4
T stage 2.3 ± 0.5 3.5 ± 0.5 3.0 ± 0.5
Metastatic sites None Bone Bone with
lymph nodes
VEGF-C mRNA expression
Negative 4 6 0
Weakly positive 1 3 3
Strongly positive 2 1 6
Formalin-fixed, paraffin-embedded tissues were hybridized with T-T
dimerized antisense probes for VEGF-C and hybridized probes were
visualized by using anti-T-T antibody followed by peroxidase reaction. No
staining of tumour cells is indicated as ‘negative’. ‘Weakly positive’ indicates
a positive staining restricted to the perinuclear area, and ‘strongly positive’
indicates diffuse cytoplasmic staining in the tumour cells. Group 3 (with
lymph node metastasis) demonstrated significantly stronger VEGF-C mRNA
expression than other groups (without lymph node metastasis; P = 0.0083,
by the c2 test).
     
     
     
Figure 1 VEGF-C mRNA expression in human prostatic carcinoma cell
lines, PC-3 (A–G), LNCaP (H) and DU-145 (I) by using the non-radioactive in
situ hybridization method. (A) 28S rRNA antisense probe; (B) VEGF-C sense
probe; (C, H, I) VEGF-C antisense probe; (D) competition with excess
amount (50-fold) of unlabelled probe; (E) competition with excess amount
(50-fold) of non-homologous unlabelled oligo-DNA; (F) hybridization with
antisense probe followed by washing at excessively high stringency; (G)
treatment with RNase-A before hybridization with VEGF-C antisense probe.
Magnification ´ 400VEGF-C mRNA expression in human prostatic
carcinoma tissues
Twenty-six human prostatic carcinoma samples were examined
for the expression of VEGF-C mRNA by ISH. Sixteen specimens
out of 26 (61.5%) were estimated as positive, in which the cancer
epithelial cells were positive for VEGF-C mRNA, while other
types of cells, such as basal cells, stromal cells, endothelial cells
and vascular smooth muscle cells, were negative for VEGF-C
expression. The staining for VEGF-C mRNA was localized to the
cytoplasmic area of epithelial cells. A typical staining is shown in
Figure 2. In group 1, three specimens out of seven (42.9%) were
estimated as positive (two strongly positive and one weakly posi-
tive). In group 2, four specimens out of ten (40%) were positive for
VEGF-C mRNA, and in group 3, all nine specimens (100%) were
positive (Table 1). Group 3 (with lymph node metastases) demon-
strated significantly higher VEGF-C mRNA expression than other
groups (without lymph node metastases) (P = 0.0083) and no
significant difference was observed between localized disease and
advanced disease (group 1 vs group 2). These data demonstrate
that the expression of VEGF-C mRNA in prostatic carcinoma cells
is closely associated with the presence of lymph node metastasis.
VEGFR-3 protein expression assessed by IHC
Receptors for VEGF-C were identified as VEGFR-2 and -3
(Joukov et al, 1996). Since the expression of VEGFR-3 is highly
restricted to lymphatic endothelial cells (Kaipainen et al, 1995), it
has been suggested that VEGF-C is involved in lymphangiogen-
esis (increase in the number of lymphatic vessels) in differentiated
tissues. To examine the role of VEGF-C expression in prostatic
carcinoma, VEGFR-3 expression was studied in two fresh frozen
sections from each of VEGF-C-negative, VEGF-C weakly posi-
tive and VEGF-C strongly positive groups by IHC. Two speci-
mens in each group showed representative results and the typical
tumour areas from each group are shown in Figure 3. In the
VEGF-C mRNA-negative specimens, VEGFR-3-positive vessels
were hardly observed, as shown in Figure 3A. However, in the
VEGF-C mRNA-positive specimens, the number of VEGFR-3-
positive vessels was clearly increased in the stromal tissues
surrounding tumour nests, as shown in Figure 3B and 3C. The
VEGFR-3-positive vessels were hardly observed in the tumour
nests and none of the VEGFR-3-positive channels contained red
blood cells.
DISCUSSION
In this study, we demonstrated that the expression of VEGF-C in
human prostatic carcinoma cells was significantly correlated with
the presence of lymph node metastasis. In addition, VEGFR-3-
positive vessels (possibly lymphatic vessels), which were
observed only in tumour stromal tissue, were increased in density
when VEGF-C was expressed in the prostatic carcinoma cells,
indicating a paracrine relationship between VEGF-C expressed in
prostatic cancer cells and its receptor, VEGFR-3, expressed in
adjacent stromal tissue. This is the first demonstration of the asso-
ciation of VEGF-C expression and lymphatic dissemination of
human carcinoma.
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Figure 2 VEGF-C mRNA expression of a grade 5 prostatic carcinoma
tissue visualized by using the non-radioactive in situ hybridization method.
(A) 28S rRNA antisense probe used as a positive control; (B) VEGF-C
antisense probe; (C) VEGF-C sense probe used as a negative control.
Magnification x 200
ABC
Figure 3 VEGFR-3 expression in fresh frozen sections of prostate carcinoma tissue examined by immunohistochemistry. (A) VEGF-C mRNA-negative
specimen; (B) in VEGF-C mRNA weakly positive specimen; (C) VEGF-C mRNA strongly positive specimen. Arrows in (B) show the positive staining of VEGFR-
3. Magnification ´ 400There is no definitive marker for the identification of lymphatic
endothelial cells yet. According to recent studies (Jussila et al,
1998), the combination of anti-PAL-E and anti-CD31 immunos-
taining was useful to recognize lymphatic endothelial cells (PAL-
E-negative/CD31-positive) and VEGFR-3 expression was mostly
observed in lymphatic endothelial cells. Our results indicate that
VEGFR-3 expression could be one of the good markers of
lymphatic endothelial cells. In this study, VEGFR-3-positive cells
were found only in connective tissue stroma surrounding tumour
nests and none of the VEGFR-3-positive channels contained red
blood cells. These findings suggest that VEGFR-3-positive cells
are possibly lymphatic endothelial cells.
VEGF-C is a ligand for VEGFR-2 and -3. VEGFR-2 is expressed
in both blood vessel and lymphatic endothelial cells. In the present
study, we could not observe a remarkable difference of the blood
vessel density between VEGF-C-positive and -negative prostatic
carcinoma specimens (data not shown). Angiogenesis is stimulated
by a variety of growth factors, including fibroblast growth factors,
VEGF and transforming growth factor-b(Folkman and Shing, 1992).
In prostatic carcinoma, many of these growth factors are known to be
expressed (Steiner, 1993) and angiogenesis in prostatic carcinoma
may be regulated by these growth factors rather than VEGF-C. In
contrast, the expression of VEGFR-3 is highly restricted to lymphatic
endothelial cells. The role of the signal transduction pathway via
VEGFR-3 in the biological responses of lymphatic endothelial cells
has not been clarified yet. However, the present data is compatible
with the view that VEGF-C stimulates lymphangiogenesis in vivo. In
transgenic mice, overexpression of VEGF-C resulted in the increase
in diameter of lymphatic vessels, whereas an increase in the number
of vessels was not observed (Jeltsch et al, 1997). In the differentiated
chorioallantoic membrane, VEGF-C was stimulatory also for in vivo
lymphangiogenesis (Oh et al, 1997). The difference of VEGF-C
functions between developing and mature tissues may be due to the
presence of specific signal transduction pathways or an unidentified
specific receptor for VEGF-C, which could be expressed only in
mature lymphatic endothelial cells and could be necessary for the
increase in lymphatic vessels.
In the present study, some clinically lymph node-negative prostatic
carcinoma specimens also showed VEGF-C expression. It is possible
that VEGF-C-positive prostatic carcinoma patients without clinical
lymph node metastasis in the present study might have lymph node
metastasis at microscopic level. Nevertheless, more importantly, the
expression of VEGF-C was significantly higher in lymph node-
positive patients than in node-negative patients, suggesting that the
examination of VEGF-C expression in prostatic carcinoma tissue
may be an indicator of the presence of lymph node metastasis.
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